SP1 and prostate cancer: Thiazolidinedione derivatives (OSU-CG12) have demonstrated the ability to hinder prostate cancer progression by facilitating Sp1 degradation through modulation of Sp1 phosphorylation and ubiquitination levels (Wei et al., 2009).